摘要目的:应用细胞遗传学和分子生物学检测方法明确1例嵌合型标记染色体患者的核型及其来源。方法:抽取患者的外周血样，进行染色体核型分析、基因芯片检测和荧光原位杂交检测。结果:染色体分析结果显示患者核型为mos 47，XX，+mar [45]/48，XX, +2mar[3]/ 46，XX[52];基因芯片检测结果为arr[hg19]15q11.1q11.2(20 161 372-24 314 675)×3，重复片段约4.15 Mb；荧光原位杂交显示约50%的细胞含有的标记染色体为一条包含有双份D15Z1探针位点片段的衍生双着丝粒15号标记染色体。此标记染色体未包含Prader-Willi syndrome/Angelman syndrome综合征的 SNRPN和 PML探针位点片段。 结论:当患者的核型与其表型不一致时，将细胞遗传学与分子生物学技术相结合，可以明确患者的核型和基因定位，为其后续治疗提供更精准的遗传咨询。

abstractsObjective:To determine the origin of a mosaic small supernumerary marker chromosome (sSMC) by cytogenetic and molecular analysis.Methods:Karyotype analysis, fluorescence in situ hybridization (FISH) and SNP-array were carried out. Results:The karyotype of the patient was mos47, XX, + mar[45]/48, XX, + 2mar[3]/46, XX[52], the SNP-array result was arr[hg19]15q11.1q11.2 (20 161 372-24 314 675)×3, and the repeat fragment was about 4.15 Mb. FISH showed that approximately 50% of the cells have contained a sSMC with double D15Z1 probe site segments derived from abnormal idic(15). This sSMC did not contain SNRPN and PML probe fragments of Prader-Willi syndrome/Angelman syndrome. Conclusion:When the patient’s karyotype and phenotype are inconsistent, cytogenetic and molecular biology technologies should be combined to clarify the karyotype and gene location, so as to provide more accurate genetic consultation for the follow-up treatments.